Saikosaponin G, a triterpene glycoside, is a saikosaponin which is believed to be responsible for part of the pharmaceutical properties of Bupleuri Radix. Bupleuri Radix, dried roots of Bupleurum spp. (Apiaceae), has been used as medicine in China for over 2000 years, and it is one of the most common components of Chinese traditional medicine prescriptions for the treatment of chronic hepatitis, kidney syndrome, inflammatory diseases, and ulcers of the digestive system.
Saikosaponin F, a genuine glycoside, is a saikosaponins extracted from the methanolic extract of Bupleurum chinese DC. Saikosaponins is believed to be responsible for part of the pharmaceutical properties of Bupleuri Radix. Several saikogenins and their derivatives have anti-allergic activity, analgesic action, anti-inflammatory action, plasma cholesterol-lowering action, action for hepatic injuries, etc.
Saikosaponin B4 is a saikosaponins isolated from Bupleurum chinese DC. It is a Saikosaponins standard to help analyse and resolve the activities of herbal medicines such as Sho-saiko-to. Sho-saiko-to, is a herbal medicine which prevents liver fibrosis and the development of preneoplastic lesions by directly inhibiting the activation of stellate cells.
Safinamide is a highly selective MAO-B inhibitor in rat brain mitochondria, with an IC50 of 98 nM. safinamide inhibits MAO-B in human brain with an IC50 of 9 nM.
Sacubitril-(2S, 4S)-isomer.Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
Sacubitril, also known as AHU377, is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor blocker (valsartan). Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases.
Sacubitrilat is one of the impurities of Sacubitril which has been found to be an endopeptidase inhibitor and be effective in the treatment of hypertension and heart failure.
Sacubitril enantiomer.Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
Sacubitril, also known as AHU377 or LCZ696, is an angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases. LBQ657 inhibits the enzyme neprilysin, which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides that work mainly by reducing blood volume.
S-acetylglutathione is a glutathione derivative that has been shown to inhibit the replication of herpes simplex virus 1 (HSV-1) in human foreskin fibroblasts when used at concentrations of 5 and 10 mM.
Saccharin Sodium Dihydrate is an intense sweetener used in beverages, foods, table-top sweeteners and pharmaceutical for mulations such as tablets, powders, medicated confectionery, gels, suspensions, liquids and mouthwashes.
SA-4503 is a potent sigma receptor agonist. SA-4503 may have effects on depressive symptoms such as agitation, loss of interest, and impaired cognition, which are mediated by NMDA receptors. SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus.
S107 is a type 1 ryanodine receptor (RyR1) stabilizer that binds RyR1 and enhances the binding affinity of calstabin-1. S107 increased FKBP12 binding to RyR1 in SR vesicles in the presence of reduced glutathione and the NO-donor NOC12, with no effect in the presence of oxidized glutathione.
Ruxolitinib phosphate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
Ruxolitinib is a potent and selective JAK1/2 inhibitor with IC50 values of 3.3 nM and 2.8 nM respectively in cell-free assays, and has > 130-fold selectivity for JAK1/2 versus JAK3.
Ruscogenin is a saponin found in the root of Ophiopogon japonicus. It inhibits the expressions of TF, iNOS, and NF-kappaB p65 and is therefore a potential target for acute lung injury or sepsis. It remarkably inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV304) injured by tumor necrosis factor-alpha (TNF-alpha) in a concentration-dependent manner.
Rucaparib camsylate is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which work in DNA repair process. It was approved for the treatment of ovarian cancer, and Rubraca is proved to be a monotherapy for the patients deleterious BRCA mutation associated advanced ovarian cancer who were treated with two or more chemotherapies.
Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. So, rucaparib has been also found to be most effective in cells deficient in DNA repair, where the cells deficient are caused by exposure to genotoxic agents, such as irradiation produces DNA damage and its toxicity is augmented when the DNA repair is impaired. Increased radiosensitivity in presence of rucaparib was associated with persistent DNA breaks as determined by gamma-H2AX and p53BP1 foci. Rucaparib radiosensitizes prostate cancer cells, most effectively those that are PTEN-deficient and are expressing ETS gene fusion proteins, which inhibits NHEJ DNA repair.
Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-maximal inhibitory constant of 4.5 and 5.9 nM, respectively. The half-life of ruboxistaurin, which can be orally administered, is approximately 9h and that of its metabolite 16h, therefore allowing once-daily dosing. Based on data from clinicalTrials.gov, Children's Hospital Medical Center, Cincinnati plan a phase I/II trial of the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure on June 9, 2016.
Rubitecan is a semisynthetic agent related to camptothecin with potent antitumor and antiviral properties. Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells. This agent also prevents repair of reversible single-strand DNA breaks.
RU 58841 is a new non-steroidal antiandrogen which has potential for use in treating androgen-dependent skin disorders such as acne, hirsutism and androgen-dependent alopecia.
RTA-408 is a member of the synthetic oleanane triterpenoid class of compounds and an activator of nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2, Nfe2l2), with potential chemopreventive activity. Upon administration, RTA 408 activates the cytoprotective transcription factor Nrf2. In turn, Nrf2 translocates to the nucleus, dimerizes with a small Maf protein (sMaf), and binds to the antioxidant response element (ARE). This induces the expression of a number of cytoprotective genes, including NAD(P)H quinone oxidoreductase 1 (NQO1), sulfiredoxin 1 (Srxn1), heme oxygenase-1 (HO1, HMOX1), superoxide dismutase 1 (SOD1), gamma-glutamylcysteine synthetase (gamma-GCS), thioredoxin reductase-1 (TXNRD1), glutathione S-transferase (GST), glutamate-cysteine ligase catalytic subunit (Gclc) and glutamate-cysteine ligase regulatory subunit (Gclm), and increases the synthesis of the antioxidant glutathione (GSH). Nrf2, a leucine zipper transcription factor, plays a key role in the maintenance of redox balance and cytoprotection against oxidative stress.
5-R-Rivaroxaban is the R-isomer of Rivaroxaban, which is a novel, oral, direct Factor Xa (FXa) inhibitor. It is useful for antithrombotic agent and is a promising drug for atrial fibrillation, venous thromboembolism or thromboembolic disorders in clinic.
The hydrochloride salt form of Rotigotine which is a dopamine D2 and D3 receptor agonist and has been shown to be effective in the treatment of Parkinson's disease. IC50: 13 nM and 0.71 nM for D2 and D3 receptor respectively.
Rosuvastatin Z-Isomer Calcium Salt is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity M is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity K (2Z-isomer) is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity G calcium salt is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity G is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity FP-B (6S-isomer) calcium salt is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity FP-B (6R-isomer) calcium salt is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity D is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity C Sodium Salt is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
Rosuvastatin EP Impurity A Calcium Salt is an impurity of Rosuvastatin, which is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids.
